Mirtazapine for Methamphetamine Withdrawal
Start mirtazapine 15 mg orally at bedtime for patients with methamphetamine withdrawal experiencing insomnia, anxiety, and decreased appetite, with titration to 30 mg after 3-7 days if tolerated. This dosing is particularly advantageous in this population as mirtazapine's side effect profile—sedation, increased appetite, and weight gain—directly addresses the core withdrawal symptoms 1.
Dosing and Titration
Initial dose: 15 mg orally at bedtime 1
Titration schedule:
- Increase to 30 mg at bedtime after 3-7 days if initial dose is tolerated and symptoms persist
- The FDA label specifies dose changes should not occur in intervals less than 1-2 weeks for depression 1, but in methamphetamine withdrawal, more rapid titration to 30 mg is supported by clinical trial evidence 2, 3
- Maximum dose: 45 mg daily, though most evidence supports 30 mg as the optimal dose for methamphetamine use disorder 2, 3
The 30 mg dose appears most effective. A large phase 3 trial (n=339) demonstrated that mirtazapine 30 mg daily reduced methamphetamine use by a mean of 7.0 days over 28 days compared to 4.8 days with placebo (mean difference 2.2 days, p=0.02) 3. An earlier trial among men who have sex with men showed similar benefits, with risk ratios of 0.67 at 12 weeks and 0.75 at 24 weeks for methamphetamine-positive urine tests 2.
Duration of Treatment
Treat for 12-24 weeks initially. The strongest evidence supports:
- 12 weeks as the minimum effective duration, with benefits evident by week 12 2, 3
- Extended treatment to 24 weeks shows sustained benefits and additional reductions in HIV risk behaviors 2
- Benefits may persist beyond active treatment, with effects extending to 36 weeks in one trial 2
Reassess at 12 weeks to determine if continuation is warranted based on reduction in methamphetamine use, improvement in withdrawal symptoms, and tolerability.
Monitoring Parameters
Baseline Assessment
- Days of methamphetamine use in past 28 days (primary outcome measure)
- Insomnia severity (Athens Insomnia Scale or Insomnia Severity Index)
- Depression symptoms (Center for Epidemiologic Studies Depression Scale or similar)
- Anxiety symptoms
- Weight and appetite
- Liver function tests (mirtazapine clearance reduced ~30% in hepatic impairment) 1
Ongoing Monitoring (weeks 3,7,12,24)
- Methamphetamine use via urine drug screening and self-report
- Sleep quality and duration
- Appetite and weight (expect 2-5 kg weight gain)
- Mood and anxiety symptoms
- Adverse effects, particularly:
Safety Monitoring
- Agranulocytosis risk: While rare, obtain CBC if fever, sore throat, or other signs of infection develop 1
- QTc interval: Mirtazapine 75 mg does not prolong QTc to clinically meaningful extent 1, but caution with other QT-prolonging drugs
- Serotonin syndrome risk: Particularly if patient using other serotonergic substances
Clinical Context and Evidence Quality
The evidence for mirtazapine in methamphetamine withdrawal is moderate and growing stronger. A 2022 meta-analysis found moderate-certainty evidence for small reductions in methamphetamine use (RR=0.81,95% CI: 0.63-1.03) 4. However, the most recent 2025 phase 3 trial provides the strongest evidence to date, demonstrating clear efficacy in routine clinical practice 3.
Important nuances:
- Mirtazapine does NOT improve treatment retention 4, 3
- Depression symptom improvement is inconsistent across trials 4
- Sexual risk behavior reduction appears as a secondary benefit at 24 weeks 2
- Medication adherence in trials was suboptimal (28-39%) yet benefits were still observed 2, suggesting even partial adherence may be beneficial
Common Pitfalls and Caveats
Discontinuation rates are significant. In the phase 3 trial, 23% discontinued mirtazapine due to adverse events versus 15% on placebo 3. Most discontinuations occur early due to sedation. Counsel patients that drowsiness typically improves after 1-2 weeks.
Avoid abrupt discontinuation. Taper gradually to prevent withdrawal symptoms including rebound insomnia, nausea, and anxiety 1. A reasonable taper: reduce by 7.5 mg every 1-2 weeks.
Sedation timing is critical. Administer at bedtime to leverage sedation for insomnia treatment. Warn patients to avoid driving or operating machinery until they know how the medication affects them, particularly in the first week.
Weight gain is expected and therapeutic in this population. Unlike typical antidepressant use where weight gain is problematic, methamphetamine withdrawal patients often present with decreased appetite and weight loss. The appetite stimulation and weight gain associated with mirtazapine (mean 12% in trials) 5, 6 directly addresses these withdrawal symptoms.
Drug interactions require dose adjustment:
- Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): reduce mirtazapine dose
- Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin): may need to increase dose
- Cimetidine: reduce mirtazapine dose 1
Contraindications:
- MAOI use within 14 days 1
- Known hypersensitivity to mirtazapine
Special populations:
- Elderly: Start with 7.5 mg due to 40% lower clearance in elderly males 1
- Hepatic impairment: Reduce dose by ~30% 1
- Renal impairment (GFR <40): Reduce dose by 30-50% 1
Mechanism and Rationale
Mirtazapine's unique pharmacology makes it particularly suited for methamphetamine withdrawal. It antagonizes α2-adrenergic autoreceptors (enhancing noradrenergic activity), blocks 5-HT2 and 5-HT3 receptors (reducing anxiety), and antagonizes H1 histamine receptors (promoting sedation and appetite) 1. This profile directly counters the hyperarousal, insomnia, anxiety, and anorexia characteristic of methamphetamine withdrawal.
Off-label use acknowledgment: Mirtazapine is not FDA-approved for insomnia or substance use disorders. Its use for insomnia is common but efficacy is "not well established" per sleep medicine guidelines 5. However, for methamphetamine withdrawal specifically, the evidence base is stronger and more recent, with a 2025 phase 3 trial demonstrating clear benefits 3.